ANI Pharma (ANIP) Tops Q4 EPS Views; Issues FY15 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
ANI Pharmaceuticals (ANIP) PT Lifted to $79 at Guggenheim
February 19, 2015 12:52 PM ESTGuggenheim analyst Louise Chen reiterated a Buy rating and boosted her price target on ANI Pharmaceuticals (NASDAQ: ANIP) to $79.00 (from $65.00) following Q4 results.
Chen commented, "Post ANIP's 4Q14 beat, we remain positive on ANIP shares, as we continue to believe a large... More
